Joseph M. Lane, MD

Appointments

Assistant Dean, Hospital for Special Surgery,Weill Medical College of Cornell University and affiliated hospitals, NYC

Professor of Orthopaedic Surgery, Weill Medical College of Cornell University

Adjunct Professor, Department of Orthopaedic Surgery, Columbia University, College of Physicians & Surgeons, New York

Chief, Metabolic Bone Disease Service, Hospital for Special Surgery

Medical Director, Osteoporosis Prevention Center, Hospital for Special Surgery

Director, Clinical Research Section, Hospital for Special Surgery

Attending Orthopaedic Surgeon, Hospital for Special Surgery, The New York Hospital

 

Joseph M. Lane, MD is the author of the following articles on HSS.edu:

Selected Publications

Zohman GL, Boardman DL, Eckardt JJ, and Lane, JM: Stride Analysis after Proximal Tibial Replacement. CORR 339:180-184, 1997.

Liu SH, Panossian V, Al-Shaikh R, Tomin, E, Shepherd E, Finerman GA, and Lane JM: Morphology and Matrix Composition During Early Tendon to Bone Healing. CORR 339:253-260, 1997.

Liu SH, Al-Shaikh RA, Panossian V, Finerman GA, Lane JM: Estrogen Affects the Cellular Metabolism of the Anterior Cruciate Ligament. A Potential Explanation for Female Athletic Injury. Am J Sports Med 25(5):704-709, 1997.

Panossian V, Liu SH, Lane JM, Finerman GA: Fibroblast Growth Factor and Epidermal Growth Factor Receptors in Ligament Healing. Clinical Ortho. and Rel Research 342:173-180, 1997.

Cole BJ, Bostrom MP, Pritchard TL, Sumner DR, Tomin E, Lane JM, Weiland, AJ: Use of Bone Morphogenetic Protein-2 on Ectopic Porous Coated Implants in the Rat. Clinical Ortho. and Rel Research 345:219-228, 1997.

For more publications, please see the PubMed listing.  

Clinical Trials

• Fragile Bone Registry
• Vitamin D Status Among Trauma Patients; Acute Fractures/Non-unions vs. Primary Joint Arthroplasty (control population)
• Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures
• A Randomized Double Blind Placebo Controlled Multi-Center Parallel Group Study of One Year Duration Followed by Two Years of open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate